Katy Location

705 S. Fry Rd., Suite 115
Katy, TX 77450
Phone: 281.647.9204


West Houston Location

12121 Richmond, Suite 217
Houston, TX 77082
Phone: 832.243.1850

Clinical Research

Graduate work:

  • Effects of ozone on Arachidonic Acid metabolism in the rat lung- in vivo studies
  • Effects of Amiodarone on thyroxine in the rat heart- in vivo studies.

Clinical studies during fellowship:

  • Adherence by Internal Medicine Residents to National Guidelines for the Diagnosis and Management of Asthma- poster presentation at the American College of Allergy, Asthma and Immunology International meeting 1995
  • Ambiguity in Diagnosing Allergic Bronchopulmonary Aspergillosis- poster presentation at the American College of Allergy, Asthma and Immunology International meeting 1996.
  • Results of complete skin tests performed during a 10 year period- presentation at the regional allergy society meeting in Irvine, California.
  • Use of Itraconazole in the Management of Allergic Bronchopulmonary Aspergillosis- investigator and clinical coordinator.

Clinical trials:

  • Investigator for “An Open-Label, Multicenter Study of the Efficacy and Safety of Grepafloxacin in the Treatment of Acute Bacterial Maxillary Sinusitis”.
  • Investigator for “An Open, Controlled Extension to the MK-0476 vs. Placebo Comparison Study to Investigate the Long-Term Safety and Tolerability of MK-0476 in Patients with Chronic Asthma”.
  • Investigator for “A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Evaluation of Ranitidine for the Reduction of Severity or Prevention of Meal-Induced Heartburn”.
  • Investigator for “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Ranitidine for the Treatment of Severe Heartburn Episodes”.
  • Investigator for “A Dose Ranging, Safety, and Efficacy Trial with Zarfirlukast (Accolate) in the Treatment of Pediatric Subjects with Mild to Moderate Asthma; Up to 52 Week Open Label Safety Extension”.
  • Investigator for “A Multicenter, Randomized, Double-Blind, Eight Week Comparative Efficacy and Safety of H 199/18 40 mg and Omeprazole 20 mg in Study Subjects with Erosive Esophagitis”.
  • Sub-investigator for “A Multicenter, Open-Label Long Term Safety Study of H 199/18 40 mg in Subjects with Healed Erosive Esophagitis”.
  • Investigator for “A Randomized, Double-blind, Multicenter Comparison of the Efficacy and Safety of a 5 or 10 day Course of Grepafloxacin in the Treatment of Patients with Acute Bacterial Exacerbations of Chronic Bronchitis”.
  • Principle Investigator for “A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Clinical Trial of Four Weeks Treatment with Serevent Inhalation Aerosol, 25 mcg BID, 50 mcg BID and Placebo Administered Via a Valved Holding Chamber with Facemask in Subjects with Asthma Age 24 to 47 months”.
  • Principle Investigator for “Randomized, Open-Label, Multicenter Trial of the Safety and Effectiveness of Oral Telithromycin and Augmentin in Outpatients with Respiratory Tract Infections in Usual Care Settings”.
  • Principle Investigator for “Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril”.
  • Principle Investigator for antibiotic study in the treatment of sinusitis, phase 4.
  • Principle investigator for Excels. A long term study on Xolair anti IgE
  • Principle investigator for a new therapy option for patients with hives
  • Principle investigator for EXTRA. The use of anti IgE in mild asthma
  • Principle investigator for the safety of current inhaled steroid/long acting bronchodilators combination
©West Houston Allergy & Asthma.All rights reserved.